echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > JACC: "Lack of eyes" remediation to relieve migraines

    JACC: "Lack of eyes" remediation to relieve migraines

    • Last Update: 2021-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The occurrence rate of ovary hole not closed (PFO) in normal people is about 1/4, and in recent years more and more data show that egg round hole is associated with clinical diseases such as stroke and migraines.
    5 to July after the birth of normal people, the egg round hole appears functional closing, most infants and young children before the age of 2 years of age, the egg round hole is functionally closed, if more than 3 years old is not closed, it is called the egg round hole is not closed.
    , but the results show that about 20% to 30% of normal adults still have egg round holes that are not closed or not completely closed.
    recent studies have found a closer relationship between egg round holes and precursor migraines, mainly because some chemicals induce migraines by entering the brain circulation through unoolpted egg round holes.
    migraine is a common and gradually worsening disease, clinically with recurrent one- or two-sided throbbing headache as the main manifestation, can be accompanied by nausea, vomiting and other gastrointestinal reactions.
    Because migraines have a serious impact on the physical and mental health of patients, reduce the quality of life and work efficiency of patients, and bring serious financial burden to families and society, an in-depth understanding of the mechanisms of migraine occurrence plays a crucial role in the prevention and treatment of migraines.
    Although previous observational studies have shown that periterine ovary round hole closure (PFO) surgery is a safe means of reducing migraine frequency and duration, no randomized clinical trials have reached the primary therapeutic endpoint.
    this, a professor of cardiology from UCLA in the United States conducted a summary analysis of the trials of PFO thusers in PFO combined migraine patients.
    results were published in the latest issue of the Journal of the American College of Cardiology (JACC).
    authors reported a summary analysis of participant data from two randomized trials using Amplatzer PFO Occluder (PRIMA and PREMIUM) to assess the effectiveness and safety of throesia with or without precursor to treatment by PFO.
    The end of the study was a reduction in the number of migraine days per month, a response rate (defined as a decrease of ≥50%) per month, an average reduction in the number of migraine episodes per month, and the percentage of patients who experienced a complete cessation of migraines.
    end point is the adverse events associated with the test program and equipment.
    of the 337 subjects included, 176 were randomly assigned to PFO closure and 161 chose medication.
    in a 12-month follow-up, the following comparative data were summarized and analyzed: average reduction in migraine days per month (-3.1 days vs.-1.9 days; p -0.02), average reduction in migraine attacks per month (-2.2.2) 0 vs.-1.4;p s 0.01), and the number of subjects who experienced a complete cessation of migraines (14 .9% vs.1 .1 .7% ;p .lt;0.001).
    safety analysis, 9 surgery-related and 4 device-related adverse events occurred in 245 subjects who eventually received the device.
    but all events are short-lived and can eventually be resolved.
    the results show that, at least from a summary analysis of patient-level data, PFO closure is safe for the treatment of patients with open and combined migraines.
    PFO significantly reduced the average number of days of monthly migraines and the number of monthly migraine episodes, and freed more subjects from migraine distress completely.
    : Mojadidi MK, et al. Pooled Analysis of PFO Occluder Device Trials in Patients With PFO and Migraine. J Am Coll Cardiol. 2021 Feb 16; 77(6):667-676. doi: 10.1016/j.jacc.2020.11.068.MedSci Original Source: MedSci Original Copyright Notice: All noted on this website Source: Met Medical Or "Source: MedSci Original" text, images and audio-visual materials, copyrights are owned by Metz Medicine, without authorization, no media, website or individual may reproduce, authorized to reproduce with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.